Letters

previously participating as elector or candidate in academic election procedures in which there was at least 1 candidate with nonauthor contributions to published research articles. At present, there are no unresolved issues with respect to the aforementioned academic procedures. As of October 6, 2017, Dr Mentzelopoulos is a member of an academic election committee that will evaluate candidates with nonauthor contributions to published research articles.


CORRECTION

Incorrect Data in Tables: In the Original Investigation entitled “Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients” published in the October 17, 2017, issue of JAMA, incorrect data were reported in tables. In Tables 2 and 3, the values reported in the “No. of Deaths Among Recipients/No. of Recipients” columns in the “Male Recipients” and “Female Recipients” sections should have been the numbers of ever-pregnant or never-pregnant female donors minus the numbers of male donors (reference category), rather than the total numbers of deaths and recipients. This article was corrected online.


Omitted Conflict of Interest Disclosures: In the Original Investigation entitled “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet,” published in the November 28, 2017, issue of JAMA, there were omissions in the Conflict of Interest Disclosures section. The following disclosures should have included: “Dr Bhasin reported receiving research grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, the National Institute of Nursing Research, Abbott, Ligand, Transition Therapeutics, Regeneron, Novartis, Althea, Biosensics, and Merck; receiving consulting fees from Sanofi and Regeneron; serving as the chair of the Endocrine Society’s expert panel that developed guideline for testosterone therapy of androgen deficiency in men; and serving on the American Board of Internal Medicine Endocrinology Board’s examination writing committee from 2006 to 2015 and as this committee’s chair from 2011 to 2015.” This article was corrected online.


Error in Figure: In the Original Investigation entitled “Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012” published in the January 9, 2018, issue of JAMA, an incorrect label was used in Figure 2A. In the key of Figure 2A, “SEER” should be “Observed US mortality.” This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.